Home/Indications/Oncology/Prostate Cancer

Prostate Cancer

Oncology 9 original drugs

Novel Drugs

Reformulations

Drug Targets

Oncology indication. Prostate Cancer has 9 FDA-approved novel treatments, led by TERSERA, with 879 active industry clinical trials across 15 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Prostate Cancer Market Leaders

Companies with the most FDA-approved novel Prostate Cancer drugs.

Phase 3 Readouts Pro

12 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q3 2026

PF-06821497

Pfizer

Estimated · fresh NCT06551324

Q3 2026

64Cu-SAR-bisPSMA

Clarity Pharmaceuticals Ltd

Estimated · fresh NCT06056830

Q3 2026

Copper Cu 64 PSMA I&T

Curium US LLC

Estimated · fresh NCT06235151

Unlock 9 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Prostate Cancer Treatments by Mechanism

Top 12 mechanisms across 97 industry trials with a known mechanism of action.

See full pipeline →

Androgen Receptor

10 trials 8 active 2 sponsors

Androgen Receptor Inhibitor

29 trials 3 active 4 sponsors

Kinase Inhibitor

6 trials 3 active 3 sponsors

Poly(ADP-Ribose) Polymerase Inhibitor

5 trials 3 active 1 sponsor

CYP17/PARP-1/PARP-2

13 trials 2 active 8 sponsors

AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3

6 trials 2 active 1 sponsor

AKT1/AKT2/AKT3

3 trials 2 active 1 sponsor

Programmed Death Receptor-1 Blocking Antibody

12 trials 1 active 3 sponsors

Photoenhancer

1 trials 1 active 1 sponsor

Androgen Receptor/Progesterone Receptor

1 trials 1 active 1 sponsor

Autologous Cellular Immunotherapy

7 trials 1 sponsor

Gonadotropin Releasing Hormone Receptor Antagonist

4 trials 3 sponsors

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Prostate Cancer Clinical Pipeline by Phase

883 industry-sponsored trials across 343 sponsors

View full landscape →

Showing 31 of 31 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Bayer	Darolutamide (Nubeqa, BAY1841788)	—	RECRUITING	2027-04-29	NCT05348876
Novartis	AAA617	—	RECRUITING	2033-07-20	NCT05803941
Lantheus Medical Imaging	Piflufolastat F 18 Intravenous Solution [PYLARIFY]	—	ACTIVE NOT RECRUITING	2026-09	NCT06074510
Bayer	Radium-223 dichloride (Xofigo, BAY88-8223)	—	ACTIVE NOT RECRUITING	2025-11-21	NCT04597125
AstraZeneca	olaparib	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2024-10-22	NCT05457257
Johnson & Johnson	Apalutamide	Androgen Receptor	ACTIVE NOT RECRUITING	2023-06-01	NCT04108208
Blue Earth Diagnostics	fluciclovine (18F)	—	NOT YET RECRUITING	2027-12-31	NCT07569926
Blue Earth Diagnostics	flotufolastat (18F)	—	COMPLETED	2025-08-29	NCT06604442
Astellas	Enzalutamide	Androgen Receptor Inhibitor [EPC]	COMPLETED	2024-02-20	NCT03641560
RECORDATI GROUP	Pasireotide	—	COMPLETED	2023-07-25	NCT01794793
Ferring Pharmaceuticals	Degarelix	—	COMPLETED	2020-05-15	NCT02726009
Astellas	Enzalutamide	Androgen Receptor Inhibitor [EPC]	COMPLETED	2020-03-27	NCT02918968
Astellas	Leuprolide	—	COMPLETED	2019-11-19	NCT03035032
Ipsen	Triptorelin 11.25 mg	—	COMPLETED	2019-09-09	NCT01753297
Sanofi	cabazitaxel XRP6258	—	COMPLETED	2019-03-27	NCT02485691
Zodiac Produtos Farmaceuticos S.A.	Leuprorelin Acetate (Eligard® 45 mg).	—	COMPLETED	2018-06-15	NCT05304169
Janssen Pharmaceutical K.K.	Abiraterone Acetate	CYP17/PARP-1/PARP-2	COMPLETED	2017-12-31	NCT02405858
Pfizer	Enzalutamide	Androgen Receptor Inhibitor [EPC]	COMPLETED	2016-11-15	NCT01995513
Astellas	Enzalutamide	Androgen Receptor Inhibitor [EPC]	COMPLETED	2016-05-08	NCT02116582
Sanofi	CABAZITAXEL XRP6258	—	COMPLETED	2016-03	NCT02074137
Astellas	Enzalutamide	Androgen Receptor Inhibitor [EPC]	COMPLETED	2016-02-01	NCT01977651
Sanofi	CABAZITAXEL XRP6258	—	COMPLETED	2016-02	NCT02441894
Axogen Corporation	—	—	COMPLETED	2015-04	NCT00953277
Sanofi	CABAZITAXEL (XRP6258)	—	COMPLETED	2014-01	NCT01649635
HanAll BioPharma Co., Ltd.	ELIGARD 22.5mg	—	COMPLETED	2013-05	NCT01511874
Watson Pharmaceuticals	Triptorelin pamoate	GnRH receptor	COMPLETED	2011-04	NCT01161563
AstraZeneca	Zoladex and Casodex	—	TERMINATED	2022-11-09	NCT03971110
Astellas	Enzalutamide	Androgen Receptor Inhibitor [EPC]	TERMINATED	2017-03-15	NCT02441517
Astellas	Eligard	—	TERMINATED	2015-08	NCT01933022
Advanced Medical Diagnostics s.a.	—	—	TERMINATED	2014-07	NCT01950871
Ipsen	Decapeptyl® SR 22.5mg	—	TERMINATED	2014-02	NCT01673984

Showing 100 of 179 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Clarity Pharmaceuticals Ltd	64Cu-SAR-bisPSMA	—	RECRUITING	2026-09	NCT06056830
Curium US LLC	Copper Cu 64 PSMA I&T	—	RECRUITING	2026-09	NCT06235151
Pfizer	PF-06821497	—	RECRUITING	2026-12-02	NCT06629779
Jiangsu HengRui Medicine Co., Ltd.	Rezvilutamide Tablets	—	RECRUITING	2027-03	NCT07241416
ABX advanced biochemical compounds GmbH	[18F]PSMA-1007	—	RECRUITING	2027-03	NCT06122584
Bristol-Myers Squibb	BMS-986365	—	RECRUITING	2027-09-12	NCT06764485
Johnson & Johnson	Pasritamig	—	RECRUITING	2027-11-19	NCT07225946
Telix Pharmaceuticals (Innovations) Pty Limited	177Lu-TLX591	—	RECRUITING	2027-12	NCT06520345
Jiangsu HengRui Medicine Co., Ltd.	HRS-4357 injection	—	RECRUITING	2027-12	NCT07311694
Novartis	AAA617	—	RECRUITING	2028-04-25	NCT05939414
Merck	Opevesostat	—	RECRUITING	2028-05-10	NCT06136650
Five Eleven Pharma, Inc.	—	—	RECRUITING	2028-06-01	NCT05381103
Merck	Ifinatamab deruxtecan	—	RECRUITING	2028-06-26	NCT06925737
Novartis	Investigators choice of SoC	—	RECRUITING	2028-06-27	NCT06780670
Merck	Opevesostat	—	RECRUITING	2028-08-02	NCT06136624
Pfizer	Mevrometostat	—	RECRUITING	2028-09-12	NCT07028853
Novartis	AAA817	—	RECRUITING	2028-09-29	NCT06855277
AstraZeneca	AZD2265	—	RECRUITING	2029-02-13	NCT07611110
Amgen	Xaluritamig	—	RECRUITING	2030-01-07	NCT07213674
BioNTech SE	BNT324	—	RECRUITING	2031-02	NCT07365995
AstraZeneca	Saruparib	—	RECRUITING	2033-03-31	NCT06952803
Telix Pharmaceuticals (Innovations) Pty Limited	68Ga-PSMA-11	—	RECRUITING	2026-06	NCT07052214
HTA Co., Ltd.	Florastamin[18F] Injection	—	RECRUITING	2026-01-01	NCT06754085
Telix Pharmaceuticals (Innovations) Pty Limited	68Ga-PSMA-11	—	RECRUITING	2025-12-30	NCT05847348
Dongkook Pharmaceutical Co., Ltd.	DKF-MA102	—	RECRUITING	2025-05-20	NCT06490328
Pfizer	PF-06821497	—	ACTIVE NOT RECRUITING	2026-07-13	NCT06551324
Johnson & Johnson	Apalutamide	Androgen Receptor	ACTIVE NOT RECRUITING	2026-10-12	NCT05884398
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair	Abiraterone - Usual	—	ACTIVE NOT RECRUITING	2026-11-18	NCT03348670
Johnson & Johnson	Apalutamide	Androgen Receptor	ACTIVE NOT RECRUITING	2026-12-01	NCT03767244
Clarity Pharmaceuticals Ltd	64Cu-SAR-bisPSMA	—	ACTIVE NOT RECRUITING	2026-12-31	NCT06970847
Jiangsu HengRui Medicine Co., Ltd.	Fuzuloparib , Abiraterone acetate and Prednisone	—	ACTIVE NOT RECRUITING	2026-12-31	NCT04691804
Bayer	Darolutamide (BAY1841788, Nubeqa)	—	ACTIVE NOT RECRUITING	2027-07-30	NCT05794906
AstraZeneca	Saruparib	—	ACTIVE NOT RECRUITING	2027-09-30	NCT06120491
Amgen	Xaluritamig	—	ACTIVE NOT RECRUITING	2029-01-02	NCT06691984
Janssen Pharmaceutica N.V., Belgium	LHRHa	—	ACTIVE NOT RECRUITING	2029-08-27	NCT04557059
Aragon Pharmaceuticals, Inc.	Apalutamide	Androgen Receptor	ACTIVE NOT RECRUITING	2026-06-30	NCT02531516
AstraZeneca	capivasertib	AKT1/AKT2/AKT3	ACTIVE NOT RECRUITING	2026-03-04	NCT05348577
Pfizer	talazoparib plus enzalutamide	—	ACTIVE NOT RECRUITING	2026-02-18	NCT04821622
Novartis	177Lu-PSMA-617	—	ACTIVE NOT RECRUITING	2025-01-13	NCT04720157
Johnson & Johnson	Niraparib	—	ACTIVE NOT RECRUITING	2025-01-07	NCT04497844
AstraZeneca	Capivasertib	AKT1/AKT2/AKT3	ACTIVE NOT RECRUITING	2024-10-07	NCT04493853
Candel Therapeutics, Inc.	Aglatimagene besadenovec + valacyclovir	—	ACTIVE NOT RECRUITING	2024-08	NCT01436968
ITEL Telecomunicazioni Srl	Radiopharmaceutical 18F-JK-PSMA-7	—	ACTIVE NOT RECRUITING	2024-06	NCT05622162
Exelixis	Cabozantinib	AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3	ACTIVE NOT RECRUITING	2024-04-19	NCT04446117
Eli Lilly	Abemaciclib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2024-02-15	NCT05288166
AstraZeneca	olaparib	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2024-01-22	NCT05171816
Eli Lilly	Abemaciclib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2024-01-02	NCT03706365
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company	[Lu-177]-PNT2002	—	ACTIVE NOT RECRUITING	2023-11-01	NCT04647526
Pfizer	Enzalutamide	Androgen Receptor Inhibitor [EPC]	ACTIVE NOT RECRUITING	2023-01-31	NCT02319837
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	ACTIVE NOT RECRUITING	2022-12-12	NCT03834493
Astellas	Enzalutamide	Androgen Receptor Inhibitor [EPC]	ACTIVE NOT RECRUITING	2022-11-18	NCT04076059
Novartis	177Lu-PSMA-617	—	ACTIVE NOT RECRUITING	2022-10-02	NCT04689828
AstraZeneca	olaparib	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2021-07-30	NCT03732820
Aragon Pharmaceuticals, Inc.	Apalutamide	Androgen Receptor	ACTIVE NOT RECRUITING	2020-09-07	NCT02489318
Aragon Pharmaceuticals, Inc.	Apalutamide	Androgen Receptor	ACTIVE NOT RECRUITING	2018-03-19	NCT02257736
Aragon Pharmaceuticals, Inc.	Apalutamide	Androgen Receptor	ACTIVE NOT RECRUITING	2017-05-19	NCT01946204
Qilu Pharmaceutical Co., Ltd.	QLG1080	—	NOT YET RECRUITING	2026-11	NCT06837896
Norroy Bioscience Co., LTD	68-Ga-NYM032	—	NOT YET RECRUITING	2027-06-30	NCT07615101
Qilu Pharmaceutical Co., Ltd.	QLC5508	—	NOT YET RECRUITING	2028-06-20	NCT07632690
Norroy Bioscience Co., LTD	—	—	NOT YET RECRUITING	2028-06-30	NCT07649122
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B01D1	—	NOT YET RECRUITING	2028-12	NCT07641855
Exelixis	Cabozantinib	AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3	NOT YET RECRUITING	2030-05-31	NCT07620574
Curium US LLC	Copper Cu 64 PSMA I&T	—	COMPLETED	2025-02-18	NCT06235099
Sumitomo Pharma America, Inc.	Relugolix	Gonadotropin Releasing Hormone Receptor Antagonist [EPC]	COMPLETED	2024-12-31	NCT05605964
Ipsen	Triptorelin pamoate (embonate) salt	—	COMPLETED	2024-08-20	NCT05590793
Ipsen	Triptorelin embonate 22.5 mg	—	COMPLETED	2024-07-08	NCT05458856
Bayer	Darolutamide (Nubeqa, BAY1841788)	—	COMPLETED	2024-06-07	NCT04736199
Changchun GeneScience Pharmaceutical Co., Ltd.	Leuprolide Injectable Emulsion (CAMCEVI®)	—	COMPLETED	2023-11-30	NCT06984159
Eurofarma Laboratorios S.A.	Inj. Goserelin (Test) Subcutaneously	—	COMPLETED	2023-11-30	NCT03936218
Novartis	[18F]CTT1057	—	COMPLETED	2023-11-24	NCT04838626
Novartis	[18F]CTT1057	—	COMPLETED	2023-11-23	NCT04838613
ABX advanced biochemical compounds GmbH	[18F]PSMA-1007	—	COMPLETED	2023-06-23	NCT04742361
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2023-06-01	NCT04100018
pharmaand GmbH	Rucaparib	—	COMPLETED	2023-03-08	NCT04676334
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2022-10-31	NCT04191096
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2022-10-31	NCT04934722
Tavanta Therapeutics	TAVT-45	—	COMPLETED	2022-10-20	NCT04887506
pharmaand GmbH	Rucaparib	—	COMPLETED	2022-08-25	NCT02975934
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2022-06-20	NCT03834506
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2022-03-14	NCT03834519
Bayer	BAY1841788 / darolutamide (ODM-201)	—	COMPLETED	2021-10-25	NCT02799602
Blue Earth Diagnostics	rhPSMA-7.3 (18F) Injection	—	COMPLETED	2021-06-21	NCT04186819
Blue Earth Diagnostics	rhPSMA-7.3 (18F) Injection	—	COMPLETED	2021-04-28	NCT04186845
Johnson & Johnson	Abiraterone acetate	CYP17/PARP-1/PARP-2	COMPLETED	2021-04-22	NCT01517802
Luye Pharma Group Ltd.	LY01005 3.6 mg	—	COMPLETED	2021-03-09	NCT04563936
Endocyte	177Lu-PSMA-617	—	COMPLETED	2021-01-27	NCT03511664
AB Science	Masitinib	—	COMPLETED	2020-12-15	NCT03761225
ABX advanced biochemical compounds GmbH	F-18-PSMA-1007	—	COMPLETED	2020-10-30	NCT04102553
Astellas	Enzalutamide	Androgen Receptor Inhibitor [EPC]	COMPLETED	2020-04-30	NCT02288247
Roche	Ipatasertib	—	COMPLETED	2020-03-16	NCT03072238
SOTIO a.s.	DCVAC/PCa	—	COMPLETED	2020-01-28	NCT02111577
Myovant Sciences GmbH	Relugolix	Gonadotropin Releasing Hormone Receptor Antagonist [EPC]	COMPLETED	2019-10-25	NCT03085095
Progenics Pharmaceuticals, Inc.	18F-DCFPyL	—	COMPLETED	2019-08-29	NCT03739684
Roche	Atezolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2019-06-24	NCT03016312
AstraZeneca	olaparib	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	COMPLETED	2019-06-04	NCT02987543
Foresee Pharmaceuticals Co., Ltd.	Leuprolide Mesylate	—	COMPLETED	2018-11-19	NCT03261999
Astellas	Enzalutamide	Androgen Receptor Inhibitor [EPC]	COMPLETED	2018-10-14	NCT02677896
Bayer	Darolutamide (Nubeqa, BAY1841788)	—	COMPLETED	2018-09-03	NCT02200614
Amgen	Denosumab	RANK Ligand Inhibitor [EPC]	COMPLETED	2018-08-10	NCT01419717
Progenics Pharmaceuticals, Inc.	18F-DCFPyL Injection	—	COMPLETED	2018-07	NCT02981368

Showing 100 of 373 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Candel Therapeutics, Inc.	aglatimagene besadenovec + valacyclovir	—	RECRUITING	2026-08	NCT07332000
AtlasMedx, Incorporated	AMXI-5001:Dose Escalation Phase I	—	RECRUITING	2026-08	NCT04503265
PMV Pharmaceuticals, Inc	rezatapopt	—	RECRUITING	2026-08-15	NCT04585750
Blue Earth Therapeutics Ltd	Lutetium (177Lu) rhPSMA-10.1 Injection	—	RECRUITING	2026-08-27	NCT05413850
Clarity Pharmaceuticals Ltd	64Cu-SAR-bisPSMA	—	RECRUITING	2026-09	NCT04868604
AstraZeneca	AZD0754	—	RECRUITING	2026-11-24	NCT06267729
Zenith Epigenetics	ZEN003694	—	RECRUITING	2026-12	NCT04986423
858 Therapeutics, Inc.	ETX-19477	—	RECRUITING	2026-12	NCT06395519
Qilu Pharmaceutical Co., Ltd.	QLC5508	—	RECRUITING	2026-12	NCT07198633
Curasight	64Cu-DOTA-AE105	—	RECRUITING	2027-01-30	NCT06474806
MediLink Therapeutics (Suzhou) Co., Ltd.	YL201 for Injection	—	RECRUITING	2027-02	NCT06241846
Cellvax Therapeutics Inc	FK-PC101	—	RECRUITING	2027-02-02	NCT06636682
Apollo Therapeutics Ltd	APL-5125	—	RECRUITING	2027-04	NCT06399757
CuraCell TX AB	CC-38	—	RECRUITING	2027-04	NCT07255664
Parabilis Medicines, Inc.	FOG-001	—	RECRUITING	2027-04-01	NCT05919264
Syntrix Biosystems, Inc.	SX-682	—	RECRUITING	2027-06-30	NCT06228053
SpectraCure AB	Verteporfin	Photoenhancer [EPC]	RECRUITING	2027-07-31	NCT03067051
Daiichi Sankyo	HER3-DXd	—	RECRUITING	2027-09-01	NCT06172478
ImmunoGenesis	Evofosfamide	—	RECRUITING	2027-10	NCT06782555
AstraZeneca	Datopotamab deruxtecan (Dato-DXd)	—	RECRUITING	2027-10-01	NCT05489211
Filamon LTD	A novel hGIIA-Vimentin Inhibitor	—	RECRUITING	2027-10-26	NCT06926075
Jiangsu HengRui Medicine Co., Ltd.	SHR-4394	—	RECRUITING	2027-11	NCT07407283
Regeneron	REGN5678	—	RECRUITING	2027-11-15	NCT03972657
AstraZeneca	AZD8359	—	RECRUITING	2027-11-17	NCT07529717
Roche	GDC-1261	—	RECRUITING	2027-11-30	NCT07567846
Radiopharm Theranostics, Ltd	177Lu-BetaBart	—	RECRUITING	2027-12	NCT07189871
Phanes Therapeutics	Peluntamig (PT217)	—	RECRUITING	2027-12	NCT05652686
C Ray Therapeutics	Radiopharmaceuticals	—	RECRUITING	2027-12-30	NCT07567521
Sun Pharmaceutical Industries Limited	Abiraterone acetate	CYP17/PARP-1/PARP-2	RECRUITING	2027-12-31	NCT05422911
SpectraCure AB	Verteporfin Injection	—	RECRUITING	2028-01	NCT06807359
Celcuity Inc	Gedatolisib	—	RECRUITING	2028-01	NCT06190899
Jacobio Pharmaceuticals Co., Ltd.	JAB-8263	—	RECRUITING	2028-01	NCT04686682
Shenzhen Ionova Life Sciences Co., Ltd.	INV-9956	—	RECRUITING	2028-01-17	NCT06609005
Roche	Inavolisib	Kinase Inhibitor [EPC]	RECRUITING	2028-03-31	NCT07287150
Kyntra Bio	FG-3246	—	RECRUITING	2028-03-31	NCT06842498
Halda Therapeutics OpCo, Inc.	HLD-0915 Hard Capsule	—	RECRUITING	2028-04	NCT06800313
Syncromune, Inc.	SV-102	—	RECRUITING	2028-04-14	NCT06533644
Bayer	Darolutamide	Androgen Receptor/Progesterone Receptor	RECRUITING	2028-06-15	NCT07450599
Pathos AI, Inc.	Pocenbrodib	—	RECRUITING	2028-06-30	NCT06785636
Novartis	AMO959	—	RECRUITING	2028-07-10	NCT07226986
ModeX Therapeutics, An OPKO Health Company	MDX2001	—	RECRUITING	2028-08	NCT06239194
Tanabe Pharma America, Inc.	MT-4561	—	RECRUITING	2028-08	NCT06943521
Evopoint Biosciences Inc.	XNW5004	—	RECRUITING	2028-08	NCT06022757
Radiopharm Theranostics, Ltd	161Tb RAD402	—	RECRUITING	2028-11-30	NCT07259213
Jiangsu HengRui Medicine Co., Ltd.	HS-20093 for Injection	—	RECRUITING	2028-12	NCT07230106
Acerand Therapeutics (Shanghai) Limited	ACE-86225106 tablet	—	RECRUITING	2028-12-21	NCT06380660
Merck	Opevesostat	—	RECRUITING	2029-01-15	NCT06353386
AstraZeneca	AZD0516	—	RECRUITING	2029-01-18	NCT07181161
AstraZeneca	AZD9750	—	RECRUITING	2029-01-26	NCT07336446
AdvanCell Pty Limited	[²¹²Pb]Pb-ADVC001 (Phase 1b)	—	RECRUITING	2029-01-31	NCT05720130
AstraZeneca	AZD6621	—	RECRUITING	2029-03-29	NCT07192614
Arsenal Biosciences, Inc.	AB-3028	—	RECRUITING	2029-05	NCT07285694
Pfizer	PF-07248144	—	RECRUITING	2029-07-13	NCT04606446
Astellas	enzalutamide	Androgen Receptor Inhibitor [EPC]	RECRUITING	2029-07-31	NCT02960022
MBrace Therapeutics	ADC	—	RECRUITING	2029-09-30	NCT07145255
Minghui Pharmaceutical (Hangzhou) Ltd	MHB048C for Injection	—	RECRUITING	2029-10	NCT07192120
Novartis	Tulmimetostat DL1 QD	—	RECRUITING	2029-11-09	NCT07206056
Novartis	Tulmimetostat	—	RECRUITING	2030-02-27	NCT04104776
Regeneron	REGN4336	—	RECRUITING	2030-03-28	NCT05125016
Novartis	GVV858	—	RECRUITING	2031-05-09	NCT07288359
Dendreon	Sipuleucel-T Injection	—	RECRUITING	2031-12-31	NCT06134232
Novartis	JSB462	—	RECRUITING	2032-03-29	NCT06991556
Astellas	ASP5541	—	RECRUITING	2032-05-31	NCT07005154
Novartis	Tulmimetostat	—	RECRUITING	2032-08-02	NCT07190300
Portage Biotech	TT-10	—	RECRUITING	2026-06-01	NCT04969315
Jiangsu HengRui Medicine Co., Ltd.	HRS-5041 tablets	—	RECRUITING	2026-06	NCT06568094
Evopoint Biosciences Inc.	XNW5004	—	RECRUITING	2026-05-13	NCT06702995
Bivision Pharmaceuticals, Inc.	Lutetium Lu 177 JH020002 Injection	—	RECRUITING	2026-05	NCT06139575
Hinova Pharmaceuticals Inc.	HP518 - Dose Escalation	—	RECRUITING	2026-03	NCT06155084
Convergent Therapeutics	In-111 rosopatamab tetraxetan	—	RECRUITING	2025-12	NCT06549465
RemeGen Co., Ltd.	Disitamab Vedotin Injection	—	RECRUITING	2025-12	NCT06227156
Sinotau Pharmaceutical Group	Phase I:[177Lu]Lu-XT033 Injection	—	RECRUITING	2025-12	NCT06081686
Jiangsu HengRui Medicine Co., Ltd.	HRS-1167 tablets	—	RECRUITING	2025-11-30	NCT06689163
Biozeus Biopharmaceutical S.A.	Tadalafil 5mg	—	RECRUITING	2024-12-31	NCT05558007
Hansoh BioMedical R&D Company	HS-20093	—	RECRUITING	2024-12-31	NCT06001255
Orion Corporation, Orion Pharma	ODM-208	—	ACTIVE NOT RECRUITING	2026-07-31	NCT03436485
Pfizer	PF-07220060	—	ACTIVE NOT RECRUITING	2026-09-23	NCT04557449
Novartis	AAA617	—	ACTIVE NOT RECRUITING	2026-10-15	NCT06894511
Novartis	225Ac-PSMA-R2	—	ACTIVE NOT RECRUITING	2026-11-19	NCT05983198
OncoC4, Inc.	ONC-392 low	—	ACTIVE NOT RECRUITING	2026-11-30	NCT05682443
Sapience Therapeutics	ST101	—	ACTIVE NOT RECRUITING	2026-12	NCT04478279
Novartis	AAA617	—	ACTIVE NOT RECRUITING	2026-12-14	NCT06004661
Novartis	AAA617	—	ACTIVE NOT RECRUITING	2026-12-23	NCT05849298
Fusion Pharmaceuticals Inc.	FPI-2265	—	ACTIVE NOT RECRUITING	2026-12-23	NCT06402331
Nuvation Bio Inc.	NUV-1511	—	ACTIVE NOT RECRUITING	2027-03	NCT06334432
Fusion Pharmaceuticals Inc.	FPI-2265	—	ACTIVE NOT RECRUITING	2027-05	NCT06909825
Novartis	ARV-766 Part A&B	—	ACTIVE NOT RECRUITING	2027-05-25	NCT05067140
AstraZeneca	AZD5305	—	ACTIVE NOT RECRUITING	2027-05-28	NCT04644068
Sensei Biotherapeutics, Inc.	SNS-101 (anti-VISTA)	—	ACTIVE NOT RECRUITING	2027-06	NCT05864144
Merck	Pembrolizumab 200 mg	—	ACTIVE NOT RECRUITING	2027-10-22	NCT02861573
AstraZeneca	AZD5305	—	ACTIVE NOT RECRUITING	2031-04-11	NCT05367440
OncoC4, Inc.	ONC-392	—	ACTIVE NOT RECRUITING	2026-06-30	NCT04140526
Debiopharm International SA	Debio 4228	—	ACTIVE NOT RECRUITING	2026-06	NCT06395753
R-Pharm International, LLC	RS-113, 160 mg	—	ACTIVE NOT RECRUITING	2026-05-14	NCT07553988
Monte Rosa Therapeutics, Inc	Oral MRT-2359	—	ACTIVE NOT RECRUITING	2026-05	NCT05546268
Xencor, Inc.	vudalimab	—	ACTIVE NOT RECRUITING	2025-10-15	NCT05032040
Norroy Bioscience Co., LTD	177Lu-NYM032 injection	—	ACTIVE NOT RECRUITING	2025-06-30	NCT06383052
Bayer	Darolutamide (BAY1841788, Nubeqa)	—	ACTIVE NOT RECRUITING	2025-05-30	NCT05059236
Fusion Pharmaceuticals Inc.	FPI-2265	—	ACTIVE NOT RECRUITING	2025-05-30	NCT05219500
Cellbion Co., Ltd.	Lu-177-DGUL	—	ACTIVE NOT RECRUITING	2024-12-31	NCT05547061

Showing 100 of 300 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
AstraZeneca	Saruparib (AZD5305)	—	RECRUITING	2026-08-17	NCT05938270
Nurix Therapeutics, Inc.	NX-1607	—	RECRUITING	2026-08-31	NCT05107674
SURGE Therapeutics	STM-416p	—	RECRUITING	2026-09	NCT06450106
Angiex, Inc.	AGX101	—	RECRUITING	2026-09-06	NCT06440005
Full-Life Technologies GmbH	[225Ac]Ac-FL-020	—	RECRUITING	2026-10	NCT06492122
Zumutor Biologics Inc.	ZM008	—	RECRUITING	2026-12	NCT06451497
Atridia Pty Ltd.	HRS-5041 Single dose of HRS-5041 orally administered	—	RECRUITING	2026-12-30	NCT06830850
Phrontline Biopharma	TJ101	—	RECRUITING	2026-12-30	NCT07181473
Tasly Pharmaceutical Group Co., Ltd	Treatment arm: TSL2109 capsules。Oral administration。	—	RECRUITING	2026-12-31	NCT07514065
Orano Med Theranostics, SAS	²¹²Pb-DOTAM-GRPR1	—	RECRUITING	2027-01	NCT05283330
Johnson & Johnson	Pasritamig	—	RECRUITING	2027-01-07	NCT07319871
Amgen	Xaluritamig	—	RECRUITING	2027-01-22	NCT06613100
Johnson & Johnson	JNJ-78278343	—	RECRUITING	2027-01-28	NCT07082920
Novartis	JSB462	—	RECRUITING	2027-01-29	NCT07174063
ViroMissile, Inc.	IDOV-Immune (oncolytic vaccinia virus)	—	RECRUITING	2027-01-31	NCT06910657
Shanghai AbelZeta Ltd.	dnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell Injection	—	RECRUITING	2027-01-31	NCT07344311
Jiangsu HengRui Medicine Co., Ltd.	SHR4394	—	RECRUITING	2027-03	NCT06783829
Beijing Biotech	ETB-DualNK-01	—	RECRUITING	2027-03-14	NCT07641049
Eli Lilly	LY4052031	—	RECRUITING	2027-05	NCT06465069
VitsGen Therapeutics Inc.	177Lu-PSMA-VG01	—	RECRUITING	2027-05-06	NCT07660211
Olema Pharmaceuticals, Inc.	OP-3136	—	RECRUITING	2027-05-30	NCT06784193
Johnson & Johnson	JNJ-78278343	—	RECRUITING	2027-06-21	NCT06095089
Roche	RO7656594	—	RECRUITING	2027-06-30	NCT05800665
Janux Therapeutics	JANX007	—	RECRUITING	2027-07	NCT05519449
Dren Bio	DR-0202	—	RECRUITING	2027-07	NCT06999187
IDEAYA Biosciences	IDE034	—	RECRUITING	2027-07-30	NCT07503808
Johnson & Johnson	Pasritamig	—	RECRUITING	2027-08-31	NCT05818683
K36 Therapeutics, Inc.	KTX-2001	—	RECRUITING	2027-09	NCT07103018
Vir Biotechnology, Inc.	VIR-5500	—	RECRUITING	2027-09-29	NCT05997615
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.	DM002	—	RECRUITING	2027-10-08	NCT06751329
Aktis Oncology, Inc.	[225Ac]Ac-AKY-2519 (therapeutic)	—	RECRUITING	2027-12	NCT07581184
Clasp Therapeutics, Inc.	CLSP-1025	—	RECRUITING	2027-12	NCT06778863
Oscotec Inc.	OCT-598	—	RECRUITING	2027-12	NCT07358806
Hansoh BioMedical R&D Company	HS-20093	—	RECRUITING	2027-12	NCT07115446
Philogen S.p.A.	[68Ga]Ga-OncoACP3	—	RECRUITING	2027-12	NCT07600554
TechnoGenesys, Inc.	(R)-9bMS	—	RECRUITING	2027-12-30	NCT06705686
Nammi Therapeutics Inc	QXL138AM Injection every 2 weeks by IV Infusion	—	RECRUITING	2027-12-31	NCT06582017
SystImmune Inc.	BL-M14D1	—	RECRUITING	2027-12-31	NCT07080242
Amgen	Xaluritamig	—	RECRUITING	2028-01-30	NCT07493512
Daiichi Sankyo	Valemetostat	—	RECRUITING	2028-01-31	NCT07244341
Acerand Therapeutics (Hong Kong) Limited	ACE-232 tablets	—	RECRUITING	2028-03-01	NCT06801236
Daiichi Sankyo	DS9051b	—	RECRUITING	2028-03-01	NCT07189403
Amgen	Xaluritamig	—	RECRUITING	2028-03-27	NCT07140900
Pfizer	Mervometostat (PF-06821497)	—	RECRUITING	2028-04-20	NCT03460977
Janux Therapeutics	JANX014	—	RECRUITING	2028-05	NCT07545811
Novartis	AAA617	—	RECRUITING	2028-11-24	NCT06531499
Bayer	225Ac-PSMA-Trillium (BAY3563254)	—	RECRUITING	2028-11-26	NCT06217822
Alpha-9 Oncology USA Inc.	[177Lu]Lu-A9-0631	—	RECRUITING	2028-12	NCT07661641
Astellas	ASP5541	—	RECRUITING	2028-12-31	NCT07339267
Deciphera Pharmaceuticals, LLC	DCC-2812	—	RECRUITING	2029-02	NCT06966024
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.	EXS74539	—	RECRUITING	2029-03	NCT07517198
AstraZeneca	AZD2287	—	RECRUITING	2029-04-16	NCT06879041
Astellas	PRL-02 injection	—	RECRUITING	2029-05-31	NCT04729114
Bristol-Myers Squibb	BMS-986460	—	RECRUITING	2029-08-24	NCT06067841
Amgen	AMG 509	—	RECRUITING	2030-03-22	NCT04221542
IDEAYA Biosciences	IDE574	—	RECRUITING	2030-03-30	NCT07540572
Hangzhou DAC Biotechnology Co., Ltd.	DXC008	—	RECRUITING	2030-04	NCT06926283
Novartis	INR731	—	RECRUITING	2030-06-03	NCT07570979
Exelixis	Zanzalintinib	—	RECRUITING	2030-06-28	NCT05176483
Hangzhou DAC Biotechnology Co., Ltd.	DXC014	—	RECRUITING	2030-10-20	NCT07177937
Novartis	225Ac-ETN029	—	RECRUITING	2031-08-29	NCT07006727
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd	SYN818	—	RECRUITING	2026-06-30	NCT06666270
Jiangsu Hansoh Pharmaceutical Co., Ltd.	HS-10502 + NHA	—	RECRUITING	2026-05-07	NCT06769425
Sinotau Pharmaceutical Group	Flotufolastat F-18 Injection	—	RECRUITING	2025-12-31	NCT07149831
Nova Therapeutics LLC	CART-PSMA cells	—	RECRUITING	2025-12-01	NCT05656573
ORIC Pharmaceuticals	ORIC-944	—	RECRUITING	2025-12	NCT05413421
Oxford Vacmedix UK Ltd.	OVM-200	—	RECRUITING	2025-11-30	NCT05104515
Jiangsu HengRui Medicine Co., Ltd.	HRS-5041	—	RECRUITING	2025-08-31	NCT05942001
Epigenetix, Inc.	EP31670	—	RECRUITING	2025-05	NCT05488548
Novartis	[68Ga]Ga-PSMA-11	—	ACTIVE NOT RECRUITING	2026-08-24	NCT06379217
BeiGene	BG-68501	—	ACTIVE NOT RECRUITING	2026-08-31	NCT06257264
Exelixis	XL092	—	ACTIVE NOT RECRUITING	2026-08-31	NCT03845166
IDEAYA Biosciences	IDE-161	—	ACTIVE NOT RECRUITING	2026-10	NCT05787587
Amgen	Xaluritamig	—	ACTIVE NOT RECRUITING	2026-10-08	NCT06555796
Johnson & Johnson	JNJ-69086420	—	ACTIVE NOT RECRUITING	2026-12-08	NCT04644770
Johnson & Johnson	ARX517	—	ACTIVE NOT RECRUITING	2026-12-31	NCT04662580
Endocyte	—	—	ACTIVE NOT RECRUITING	2027-01-01	NCT04597411
Johnson & Johnson	JNJ-78278343	—	ACTIVE NOT RECRUITING	2027-02-10	NCT04898634
Eli Lilly	LY4101174	—	ACTIVE NOT RECRUITING	2027-03	NCT06238479
NeoTX Therapeutics Ltd.	—	—	ACTIVE NOT RECRUITING	2027-03-01	NCT03983954
AbbVie	ABBV-969	—	ACTIVE NOT RECRUITING	2027-05	NCT06318273
MOMA Therapeutics	MOMA-313	—	ACTIVE NOT RECRUITING	2027-05-31	NCT06545942
Bayer	BAY3546828	—	ACTIVE NOT RECRUITING	2027-06-08	NCT06052306
Eli Lilly	[Ac-225]-PSMA-62 (mCRPC)	—	ACTIVE NOT RECRUITING	2027-09	NCT06229366
ARTBIO Inc.	AB001	—	ACTIVE NOT RECRUITING	2027-11-03	NCT07214961
Atavistik Bio, Inc	ATV-1601	—	ACTIVE NOT RECRUITING	2028-08-31	NCT07038369
C Ray Therapeutics	Intravenous (IV) single dose	—	ACTIVE NOT RECRUITING	2026-04-01	NCT07236112
Theratechnologies	TH1902	—	ACTIVE NOT RECRUITING	2025-12	NCT04706962
NGM Biopharmaceuticals, Inc	NGM831	—	ACTIVE NOT RECRUITING	2025-07	NCT05215574
Agenus Inc.	Botensilimab	—	ACTIVE NOT RECRUITING	2025-01-13	NCT03860272
Exelixis	cabozantinib	AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3	ACTIVE NOT RECRUITING	2023-02-21	NCT03170960
Johnson & Johnson	Niraparib	—	ACTIVE NOT RECRUITING	2021-10-15	NCT04577833
Johnson & Johnson	Apalutamide	Androgen Receptor	ACTIVE NOT RECRUITING	2019-07-09	NCT03523442
Aragon Pharmaceuticals, Inc.	JNJ 56021927	—	ACTIVE NOT RECRUITING	2016-11-07	NCT02592317
Aragon Pharmaceuticals, Inc.	Abiraterone Acetate	CYP17/PARP-1/PARP-2	ACTIVE NOT RECRUITING	2016-06-27	NCT02123758
Danatlas Pharmaceuticals Co., Ltd	DAT-2645 tablet	—	NOT YET RECRUITING	2026-11-01	NCT06614751
IntoCell, Inc	ITC-6146RO	—	NOT YET RECRUITING	2027-06-30	NCT07423117
Qilu Pharmaceutical Co., Ltd.	QLF4113 for injection	—	NOT YET RECRUITING	2028-01-05	NCT07636707
Moonlight Bio, Inc	ML261	—	NOT YET RECRUITING	2028-03	NCT07488923
Jiangsu HengRui Medicine Co., Ltd.	dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets	—	NOT YET RECRUITING	2028-12	NCT06099990

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Prostate Cancer

ER (Estrogen Receptor) (27) AR (Androgen Receptor) (7) PR (Progesterone Receptor) (5)

Novel Prostate Cancer Drugs by Company (New molecular entities)

9 companies have an FDA-approved novel drug for Prostate Cancer.

TERSERA 1 drug

Pfizer 1 drug

PROGENICS PHARMS INC 1 drug

Bayer 1 drug

VERITY 1 drug

BLUE EARTH 1 drug

FLOTUFOLASTAT F-18 GALLIUM

NDA 2023

SUMITOMO PHARMA AM 1 drug

Amgen 1 drug

PHARMAAND 1 drug

Reformulations (15 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

LEUPROLIDE ACETATE FOR DEPOT SUSPENSION

Prostate Cancer Drug Targets

Molecular targets of approved and investigational Prostate Cancer drugs — 15 targets tracked.

GnRH receptor 8 PSMA 5 RANKL 5 Estrogen Receptor 2 Tubulin 2 CYP17 2 PARP-1 2 PARP-2 2 GnRH 1 PARP1 1 PARP2 1 Androgen Receptor 1 Progesterone Receptor 1 Microtubules 1 PARP-3 1

Biosimilars (4 BLA approved) Click to expand

Biosimilars are biological products highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency.

BILDYOS

SHANGHAI HENLIUS BIOTECH

SAMSUNG BIOEPIS CO LTD

2025

JUBBONTI

Novartis

2024